L
Lori Mandelzweig
Researcher at Sheba Medical Center
Publications - 53
Citations - 3034
Lori Mandelzweig is an academic researcher from Sheba Medical Center. The author has contributed to research in topics: Myocardial infarction & Coronary artery disease. The author has an hindex of 26, co-authored 53 publications receiving 2925 citations. Previous affiliations of Lori Mandelzweig include Bikur Cholim Hospital & Wolfson Medical Center.
Papers
More filters
Journal ArticleDOI
The second Euro Heart Survey on acute coronary syndromes: characteristics, treatment, and outcome of patients with ACS in Europe and the Mediterranean Basin in 2004
Lori Mandelzweig,Alex Battler,Valentina Boyko,Héctor Bueno,Nicolas Danchin,Gerasimos Filippatos,Anselm K. Gitt,David Hasdai,Yonathan Hasin,Jaume Marrugat,Frans Van de Werf,Lars Wallentin,Shlomo Behar +12 more
TL;DR: Data from EHS-ACS-II suggest an increase in adherence to guidelines for treatment of ACS in comparison with EHS, and analysis of data from both surveys showed even greater improvement with respect to the use of recommended medical therapy, interventions, and outcome.
Journal ArticleDOI
Perceptual, Social, and Behavioral Factors Associated With Delays in Seeking Medical Care in Patients With Symptoms of Acute Stroke
TL;DR: Perceptual, social, and behavioral factors contribute to delay in seeking medical care in acute ischemic stroke beyond demographic and clinical variables, and, when combined, further increase risk of delay.
Journal ArticleDOI
Sex Differences in Management and Outcome After Acute Myocardial Infarction in the 1990s A Prospective Observational Community-Based Study
Shmuel Gottlieb,David Harpaz,Avraham Shotan,V. Boyko,Jonathan Leor,Miriam Cohen,Lori Mandelzweig,Benjamin Mazouz,Shlomo Stern,Solomon Behar +9 more
TL;DR: In this paper, the authors assess sex differences in myocardial infarction (AMI) management in men and women with the same diagnosis and find that women with AMI are less aggressively managed than men.
Journal ArticleDOI
Peroxisome Proliferator–Activated Receptor Ligand Bezafibrate for Prevention of Type 2 Diabetes Mellitus in Patients With Coronary Artery Disease
Alexander Tenenbaum,Michael Motro,Enrique Z. Fisman,Ehud Schwammenthal,Yehuda Adler,Ilan Goldenberg,Jonathan Leor,Valentina Boyko,Lori Mandelzweig,Solomon Behar +9 more
TL;DR: Bezafibrate reduces the incidence and delays the onset of type 2 diabetes in patients with impaired fasting glucose and the combination of other recommended drugs for secondary prevention would be as efficacious as suggested by the results.
Journal ArticleDOI
Usefulness of beta-blocker therapy in patients with non-insulin-dependent diabetes mellitus and coronary artery disease
Michael Jonas,Henrietta Reicher-Reiss,Valentina Boyko,Avraham Shotan,Lori Mandelzweig,Uri Goldbourt,Solomon Behar +6 more
TL;DR: The use of β blockers in the high-risk subgroup of patients with combined diabetes mellitus (DM) and coronary artery disease (CAD) remains controversial as discussed by the authors, however, the benefit of β-blocker therapy in patients after myocardial infarction is well established.